- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03880656
BM-MNCs for Lower Extremity Compartment Syndrome Injury
Autologous Bone Marrow Mononuclear Cell Administration for Lower Extremity Compartment Syndrome Injury
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary objectives are to assess safety and tolerability of a high and low dose of autologous bone marrow mononuclear cells. Secondary objectives include evaluation of potential responses of the BM-MNC therapy.
This is a two-stage, randomized, unblinded, multicenter (two sites), controlled phase 1 clinical trial to evaluate the safety of two different doses of intramuscular injections of autologous bone marrow mononuclear cells, commonly known as a type of stem cell. Acute compartment syndrome injury is a mixed soft tissue injury due to a trauma that causes edema leading to excessive pressure in the muscle compartment. This type of injury frequently results in permanent reduction in function and disability.
A total of 18 participants that have undergone a fasciotomy for treatment of a lower leg compartment syndrome will be enrolled with 6 assigned to the control (observational) group, 6 to the low cell-dose group and 6 to the high cell-dose group. The treatment arm will receive a single dose (high or low) of autologous BM-MNCs 5 - 9 days post injury and fasciotomy and a minimum of 3 months of standard of care physical rehabilitation. An observational control arm will not receive cells post fasciotomy but will undergo a standard of care course of physical therapy and will be followed for comparison to assess early safety signals and potential benefit.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Natalie C Pettigrew, DPT
- Phone Number: 8583424191
- Email: terwilln@ohsu.edu
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females and males 18 - 70 years old
- Has single or multiple compartment syndrome of the lower leg that includes the anterior tibial compartment
- Trauma patients with lower extremity CS requiring fasciotomy that can be treated with autologous BM-MNC therapy on day 5-9 post-fasciotomy
- Ability to sign an informed patient consent form
- Access and willingness to complete a standard of care course of rehabilitation therapy and 24 months follow-up evaluations
- Ability to close the fasciotomy wound per physician assessment
- Anterior compartment muscle volume between 100 - 280 cc as determined by MRI/CT
- Within the institutions' clinical reference ranges for HbA1C
Negative HIV test
· - Non-fracture, closed fracture or compound fracture type I (wound less than 1cm & compound from within out) (Gustilo-Anderson classification)
- Female subjects must be of non-childbearing potential or must be using adequate contraception
- If female subject is of childbearing potential, subject must have a negative pregnancy test at screening
- Willing and able to adhere to the study schedule
Exclusion Criteria:
- Prior compartment syndrome of same limb;
- Active malignancy or has undergone treatment for a malignancy in the preceding 5 years as indicated in past medical history or self-report if medical records do not accompany subject or are unable to be collected (basal cell carcinoma non-exclusionary);
- HIV positive as indicated by past medical history, self-report, or positive HIV test;
- Diagnosis of Type 1 or Type 2 diabetes with elevated HbA1C consistent with diabetes;(controlled diabetes acceptable, diabetes medication for other diagnosis acceptable)
- Diagnosis of chronic lower extremity vascular disease as diagnosed by current physician diagnosis, indicated in past medical history, or self-report if medical records do not accompany subject or are unable to be collected;
- Patients unable to sign an informed patient consent;
- Anticipated amputation of involved limb;
- Neurological conditions (i.e. spinal cord injury or traumatic brain injury) that may prevent full participation in CS rehabilitation or potentially confound study outcome measures (i.e. balance and gait) per physician discretion
- Current systemic infection;
- Local infection of the involved muscle group;
- Use of ventilator that would preclude rehabilitation protocols;
- Lack of access or unwillingness to complete standard of care course of physical therapy rehabilitation;
- Life expectancy 12 months or less;
- Bone marrow disorders (i.e. leukemia, aplastic anemia, lymphoma) ;
- Inability to close the fasciotomy wound or lower extremity burns that may affect wound closure
- Extensive tissue loss due to debridement resulting in insufficient residual tissue for stem cell administration and subsequent engraftment
- Lower extremity compound fracture type II or III (Gustilo-Anderson classification);
- Anterior tibialis muscle volume less than 100 cc or greater than 280 cc as determined by MRI/CT;
- Evidence of any past or present clinically significant medical condition that would impair wound healing
- History or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study as determined by the investigator or the investigator's designee;
- Any reason, considered by the principal investigator or designee, to preclude subject enrollment in the study that might represent a threat to the subject's health or safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous BM-MNCs High Dose
Administration of autologous bone marrow mononuclear cells at High dose (700,000 cells/cc of tissue)
|
Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
|
No Intervention: Observational Control
Standard of care provided for subjects that have undergone a fasciotomy following a diagnosis of compartment syndrome.
No autologous bone marrow mononuclear cells will be administered.
|
|
Experimental: Autologous BM-MNCs Low Dose
Administration of autologous bone marrow mononuclear cells at a Low dose (350,000 cells/cc of tissue)
|
Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as determined by incidence of combined adverse events related to study agent intervention
Time Frame: Enrollment through 24 months
|
Local and systemic reactions, serious adverse events and unexpected serious adverse events.
|
Enrollment through 24 months
|
Efficacy as determined by muscle strength
Time Frame: 6 weeks, 3 months, 6 months, and 12 months
|
Change in muscle strength compared to baseline and contralateral leg as measured by manual muscle testing and Biodex.
|
6 weeks, 3 months, 6 months, and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as determined by evidence of tumor formation
Time Frame: Baseline through 12 months
|
Magnetic resonance imaging (MRI) and/or computed tomography (CT)
|
Baseline through 12 months
|
Efficacy as determined by muscle regeneration
Time Frame: Baseline through 12 months
|
Magnetic resonance imaging (MRI) and/or computed tomography (CT) to measure muscle volume
|
Baseline through 12 months
|
Nerve conduction
Time Frame: Baseline and 6 months
|
Nerve conduction velocity test
|
Baseline and 6 months
|
Wound healing
Time Frame: Baseline through 12 months
|
Number of days until wound closure at the site of fasciotomy of the anterior compartment.
|
Baseline through 12 months
|
Lower extremity sensation
Time Frame: Baseline through 12 months
|
Sensation as measured by Semmes Weinstein Monofilament.
|
Baseline through 12 months
|
Ankle range of motion
Time Frame: Baseline through 12 months
|
Range of Motion (ROM): active and passive dorsi/plantar flexion ROM assessed using a goniometer.
|
Baseline through 12 months
|
Gait analysis
Time Frame: Week 6 through 12 months
|
Change in gait kinematics: gait will be recorded using a Tekscan Pressure Mapping system where each sequential footstep is recorded along with synchronized video.
|
Week 6 through 12 months
|
Gait endurance
Time Frame: Week 6 through 12 months
|
Gait endurance measured using the 6-Minute Walk Test.
|
Week 6 through 12 months
|
Gait speed
Time Frame: Week 6 through 12 months
|
Gait speed measured using the 10 Meter Walk Test.
|
Week 6 through 12 months
|
Balance
Time Frame: Week 6 through 12 months
|
Balance assessed by single limb stance time.
|
Week 6 through 12 months
|
Questionnaire - Pain
Time Frame: Baseline through 24 months
|
Pain measured using the Numeric Pain Rating Scale (NPRS).
The participant is asked to make three pain ratings (0 to 10; 0 - no pain, 10 - worst pain), corresponding to current, best and worst pain experienced over the past 24 hours.
The average of the 3 ratings is used to represent the patient's level of pain over the previous 24 hours.
|
Baseline through 24 months
|
Questionnaire - Function
Time Frame: Baseline through 24 months
|
Lower extremity function assessed using the Lower Extremity Functional Scale (LEFS).
Total score (0 to 80; higher score = better outcome) is reported as a sum of 20 responses regarding functional activities (0 - extreme difficulty or unable to perform, 4 - no difficulty).
|
Baseline through 24 months
|
Questionnaire - Physical Activity
Time Frame: Baseline through 24 months
|
Physical activity measured by the international physical activity questionnaire (IPAQ).
Scores are reported as categorical (low, moderate, high) and/or continuous (metabolic equivalent minutes per week).
|
Baseline through 24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kenton W Gregory, MD, Oregon Health and Science University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00018011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Compartment Syndrome Traumatic Lower Extremity
-
MY01 Inc.Nova Scotia Health AuthorityCompletedCompartment Syndrome Traumatic Lower Extremity | Compartment Syndrome Traumatic Upper ExtremityCanada
-
University of PortsmouthPortsmouth Hospitals NHS TrustNot yet recruitingCompartment Syndrome Nontraumatic Lower ExtremityUnited Kingdom
-
US Department of Veterans AffairsMassachusetts Institute of TechnologyCompletedTraumatic Amputation of Lower ExtremityUnited States
-
University of Illinois at ChicagoNot yet recruitingTraumatic Amputation of Lower Extremity
-
Stryker OrthopaedicsCompletedTraumatic Amputation of Lower ExtremityUnited Kingdom
-
Stony Brook UniversityCompletedTraumatic Amputation of Lower ExtremityUnited States
-
VA Eastern Colorado Health Care SystemCompletedTraumatic Amputation of Lower ExtremityUnited States
-
Alicia KoontzCompletedTraumatic Amputation of Lower ExtremityUnited States
-
Miami VA Healthcare SystemCompletedTraumatic Amputation of Lower ExtremityUnited States
-
VA Eastern Colorado Health Care SystemUnited States Department of DefenseCompletedWounds and Injuries | Amputation, Traumatic | Traumatic Amputation of Lower ExtremityUnited States
Clinical Trials on Intramuscular administration of autologous BM-MNCs
-
Medical University of ViennaCompletedMyocardial InfarctionAustria
-
Chaitanya Hospital, PuneUnknown
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular DystrophyIndia
-
Chaitanya Hospital, PuneUnknown
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Objectif Recherche Vaccins SIDACompletedSafety Study Comparing a Vaccine Transcutaneous Administration to the Intramuscular Route (MANON-05)HIV Infection | Healthy VolunteersGermany
-
University Hospitals, LeicesterBritish Heart FoundationCompletedMyocardial Infarct | Bone Marrow CellsUnited Kingdom
-
TheraVitae Ltd.Unknown
-
Tisch Multiple Sclerosis Research Center of New...Completed
-
Elliot LanderCompletedAutoimmune Diseases | Osteoarthritis | Neurodegenerative Diseases | Emphysema | Erectile Dysfunction | CardiomyopathiesUnited States